Literature DB >> 6882661

Atopy--a favourable prognostic factor for survival in Hodgkin's disease.

P L Amlot, J Slaney, R Brown.   

Abstract

One hundred and forty-eight patients with Hodgkin's disease (HD) were stratified into 4 groups according to atopic status. Group 1 had a personal history of atopy and Group 2 a family history of atopy. In Groups 3 and 4 there was no history of atopy but high serum IgE levels (Group 3) and normal IgE levels (Group 4). Comparison of the survival of these groups by the logrank method showed a significant trend (P = less than 0.0001) where survival was ranked Group 1 greater than 2 greater than 3 greater than 4. Known prognostic factors in HD--age, sex, stage, symptoms and histology--had to be taken into account, since their distribution differed between the atopic groups. In Group I there was more stage IA and IIA disease and less "B" symptoms, in Group 3 more nodular sclerosis histology and more "B" symptoms and in Group 4 more lymphocyte-depleted histology and a higher mean age than expected from their distribution in the combined groups. Adjustment to allow for the variation in each of the other prognostic factors and for a combination of age, symptoms and histology still showed a significant trend of survival on the basis of atopic status. The increased survival of atopic patients suggests that atopic mechanisms or the genetic basis to atopy has a protective effect in HD either directly or by interaction with treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6882661      PMCID: PMC2011439          DOI: 10.1038/bjc.1983.176

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Reaginic antibody to tumour and alloantigens in mice.

Authors:  W N Bartholomaeus; D Keast
Journal:  Nat New Biol       Date:  1972-10-18

2.  Analysis of the Rye classification of Hodgkin's disease. The prognostic significance of cellular composition.

Authors:  L W Coppleson; H Rappaport; S B Strum; J Rose
Journal:  J Natl Cancer Inst       Date:  1973-08       Impact factor: 13.506

3.  Prognostic indicators in Hodgkin's disease.

Authors:  L M Axtell; M H Myers; L H Thomas; C W Berard; A R Kagan; G R Newell
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

4.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

5.  Hypergammaglobulinaemia E in HOdgkin's disease and its relationship to atopy or a familial predisposition to atopy.

Authors:  P L Amlot; J Slaney
Journal:  Int Arch Allergy Appl Immunol       Date:  1981

6.  Cancer and allergy.

Authors:  S Shapiro; O P Heinonen; V Siskind
Journal:  Cancer       Date:  1971-08       Impact factor: 6.860

7.  Serum immunoglobulin E levels in patients with neoplastic disease.

Authors:  T A Waldmann; J M Bull; R M Bruce; S Broder; M C Jost; S T Balestra; M E Suer
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

8.  Hodgkin's disease in the elderly.

Authors:  J J Lokich; G S Pinkus; W C Moloney
Journal:  Oncology       Date:  1974       Impact factor: 2.935

9.  Reduced tumor growth after low-dose irradiation or immunization against blastic suppressor T cells.

Authors:  A F Tilkin; N Schaaf-Lafontaine; A Van Acker; M Boccadoro; J Urbain
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

10.  The incidence of allergic disorders and cancer.

Authors:  W D Mackay
Journal:  Br J Cancer       Date:  1966-09       Impact factor: 7.640

View more
  3 in total

1.  Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.

Authors:  Lynn I Levin; Elizabeth C Breen; Brenda M Birmann; Julie L Batista; Larry I Magpantay; Yuanzhang Li; Richard F Ambinder; Nancy E Mueller; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-24       Impact factor: 4.254

2.  Association between common allergic symptoms and cancer in the NHANES III female cohort.

Authors:  Young Kwang Chae; Stefan Neagu; Jongoh Kim; Athanasios Smyrlis; Mahasweta Gooptu; William Tester
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

3.  Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes.

Authors:  M A Curotto de Lafaille; S Muriglan; M J Sunshine; Y Lei; N Kutchukhidze; G C Furtado; A K Wensky; D Olivares-Villagómez; J J Lafaille
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.